ExodusPoint Capital Management’s Travere Therapeutics TVTX Stock Holding History

ExodusPoint Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.2M	Buy	+73,910	New	+$2.21M	0.02%	751
2025 Q4	–	Sell	-147,348	Closed	-$3.52M	–	2080
2025 Q3	$3.52M	Buy	147,348 +19,191	+15%	+$361K	0.04%	533
2025 Q2	$1.9M	Buy	+128,157	New	+$2.12M	0.02%	765
2024 Q1	–	Sell	-37,419	Closed	-$336K	–	1972
2023 Q4	$336K	Buy	+37,419	New	+$272K	﹤0.01%	1145
2023 Q3	–	Sell	-396,060	Closed	-$6.08M	–	2159
2023 Q2	$6.08M	Buy	+396,060	New	+$7.2M	0.05%	381
2023 Q1	–	Sell	-163,993	Closed	-$3.45M	–	2138
2022 Q4	$3.45M	Buy	+163,993	New	+$3.48M	0.05%	453
2022 Q1	–	Sell	-39,120	Closed	-$1.21M	–	2692
2021 Q4	$1.21M	Buy	+39,120	New	+$1.1M	0.01%	966
2021 Q1	–	Sell	-7,372	Closed	-$201K	–	2621
2020 Q4	$201K	Buy	+7,372	New	+$172K	﹤0.01%	1732
2020 Q1	–	Sell	-18,815	Closed	-$267K	–	1650
2019 Q4	$267K	Buy	18,815 +7,262	+63%	+$92.8K	0.01%	1209
2019 Q3	$134K	Buy	+11,553	New	+$191K	﹤0.01%	1201

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ExodusPoint Capital Management's TVTX Position: Q1 2026 in Review

ExodusPoint Capital Management opened a new position in Travere Therapeutics (TVTX) in Q1 2026: 73,910 shares worth $2.2M. The stake represents 0.02% of the portfolio and ranks #751 among its holdings. This is a return to the name: ExodusPoint Capital Management previously reported a position in TVTX as recently as Q3 2025.

ExodusPoint Capital Management first reported a position in TVTX in Q3 2019 and has held it in 10 quarters since. The position peaked at $6.08M in Q2 2023. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

ExodusPoint Capital Management held 73,910 shares of Travere Therapeutics worth $2.2M as of Q1 2026.
Travere Therapeutics was a new ExodusPoint Capital Management position in Q1 2026.
Travere Therapeutics made up 0.02% of ExodusPoint Capital Management's portfolio in Q1 2026, its #751 holding.
ExodusPoint Capital Management first reported a position in Travere Therapeutics in Q3 2019 and has held it in 10 quarters since.
ExodusPoint Capital Management's Travere Therapeutics position peaked at $6.08M in Q2 2023.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.